CANA is an SGLT2 inhibitor for the treatment of T2DM. This post hoc analysis of data from the CANagliflozin cardioVascular Assessment Study (CANVAS; subjects with T2DM and a history/high risk of cardiovascular disease) evaluated CANA 100 and 300 mg compared with placebo (PBO) in subsets of subjects who were on DPP-4i (N = 316; mean age, 63 y; A1C, 8.1%; BMI, 32.3 kg/m2) or GLP-1 agonists (N = 95; mean age, 61 y; A1C, 8.1%; BMI, 37.4 kg/m2) as monotherapy or in combination with other AHAs. At Week 18, CANA 100 and 300 mg reduced A1C and body weight relative to PBO in both subsets.
Overall adverse event (AE) rates were higher with CANA than with PBO in the DPP-4i subset, and comparable or lower with CANA relative to PBO in the GLP-1 agonist subset; serious AE rates were generally higher with CANA than with PBO in both subsets. Documented hypoglycemia rates were higher with CANA 100 and 300 mg than PBO in subjects on insulin, sulfonylurea, or meglitinide in the DPP-4i subset (17/70, 29/87, and 12/74) and the GLP-1 agonist subset (11/29, 11/22, and 4/26); only 2 and 1 CANA-treated subjects who were not on these concomitant agents reported hypoglycemia in the DPP-4i and GLP-1 agonist subsets, respectively. In summary, CANA added on to DPP-4i or GLP-1 agonists (+/- other AHAs) lowered A1C, reduced body weight, and was generally well tolerated in subjects with T2DM at 18 weeks.